Skip to content
Center for Reproductive Rights
Center for Reproductive Rights

Primary Menu

  • About
    • Overview
    • The Center’s Impact
    • Center Leadership & Staff
    • Annual Reports
    • Corporate Engagement
    • Diversity, Equity and Inclusion
    • Careers
    • Contact Us
  • Work
    • Overview
    • Litigation
    • Legal Policy and Advocacy
    • Resources & Research
    • Recent Case Highlights
    • Landmark Cases
    • Cases Archive
    • World’s Abortion Laws Map
    • After Roe Fell: Abortion Laws by State
  • Issues
    • Overview
    • Abortion
    • Adolescent Sexual and Reproductive Health and Rights
    • Assisted Reproduction
    • Contraception
    • Humanitarian Settings
    • Maternal Health
    • COVID-19
  • Regions
    • Overview
    • Global Advocacy
    • Africa
    • Asia
    • Europe
    • Latin America and the Caribbean
    • United States
  • News
    • Latest News
    • Stories
    • Events
    • Center in the Spotlight
    • Press Releases
    • Statements
    • Press Room
    • Newsletters
  • Resources
    • Resources & Research
    • U.S. Abortion Rights: Resources
    • Maps
    • World Abortion Laws Map
    • After Roe Fell: Abortion Laws by State
    • Repro Red Flags: Agency Watch
  • Act
    • Overview
    • Give
    • Act
    • Learn
  • Donate
    • Become a Monthly Donor
    • Make a Donor Advised Fund Gift
    • Leave a Legacy Gift
    • Donate Gifts of Stock
    • Give a Gift in Honor
    • Attend an Event
    • Employee Matching Gifts
    • Mail a Check
  • Twitter
  • Facebook
  • Instagram
  • YouTube
  • LinkedIn
Donate
icon-hamburger icon-magnifying-glass Donate
icon-magnifying-glass-teal

Court Rules to Reinstate Significant Restrictions on Abortion Medication but Not to Revoke FDA Approval of the Drug

Center for Reproductive Rights - Center for Reproductive Rights - search logo
search Close Close icon
Center for Reproductive Rights -
Menu Close Menu Close icon
Donate

Primary Menu

  • About
    • Overview
    • The Center’s Impact
    • Center Leadership & Staff
    • Annual Reports
    • Corporate Engagement
    • Diversity, Equity and Inclusion
    • Careers
    • Contact Us
  • Work
    • Overview
    • Litigation
    • Legal Policy and Advocacy
    • Resources & Research
    • Recent Case Highlights
    • Landmark Cases
    • Cases Archive
    • World’s Abortion Laws Map
    • After Roe Fell: Abortion Laws by State
  • Issues
    • Overview
    • Abortion
    • Adolescent Sexual and Reproductive Health and Rights
    • Assisted Reproduction
    • Contraception
    • Humanitarian Settings
    • Maternal Health
    • COVID-19
  • Regions
    • Overview
    • Global Advocacy
    • Africa
    • Asia
    • Europe
    • Latin America and the Caribbean
    • United States
  • News
    • Latest News
    • Stories
    • Events
    • Center in the Spotlight
    • Press Releases
    • Statements
    • Press Room
    • Newsletters
  • Resources
    • Resources & Research
    • U.S. Abortion Rights: Resources
    • Maps
    • World Abortion Laws Map
    • After Roe Fell: Abortion Laws by State
    • Repro Red Flags: Agency Watch
  • Act
    • Overview
    • Give
    • Act
    • Learn
  • Donate
    • Become a Monthly Donor
    • Make a Donor Advised Fund Gift
    • Leave a Legacy Gift
    • Donate Gifts of Stock
    • Give a Gift in Honor
    • Attend an Event
    • Employee Matching Gifts
    • Mail a Check
  • Twitter
  • Facebook
  • Instagram
  • YouTube
  • LinkedIn

Related Content

Issues:

Abortion, Legal Restrictions

Regions:

United States

Work:

In the Courts

Type:

News, Story

Follow the Center

Donate Now

Join Now

08.18.2023

In the Courts Abortion United States News

Court Rules to Reinstate Significant Restrictions on Abortion Medication but Not to Revoke FDA Approval of the Drug

Nat Ray
Mifepristone will remain available under current regulations due to an earlier U.S. Supreme Court order.

Share

  • facebook
  • Twitter
  • linkedin
  • Email id
©Liudmila Chernetska

The Fifth Circuit Court of Appeals ruled on August 16 to reinstate burdensome pre-2016 restrictions on the abortion medication mifepristone but not to revoke the U.S. Food and Drug Administration’s (FDA’s) initial approval of the drug. The ruling in Alliance for Hippocratic Medicine v. FDA upheld part of a decision by a federal court in Texas. 

Because of an order issued by the U.S. Supreme Court in April, the Fifth Circuit’s ruling will not take effect, and mifepristone will remain available under current regulations while litigation continues. The Department of Justice has announced that it will seek Supreme Court review of the Fifth Circuit’s decision. 

Mifepristone is part of a two-drug regimen for medication abortion and was first approved by the FDA in 2000. 

The lawsuit against the FDA was filed by anti-abortion advocates in November 2022 to challenge the FDA’s initial approval of mifepristone as well as the agency’s more recent actions to increase access to the drug. 

The Fifth Circuit’s ruling left in place the FDA’s approval of the drug in 2000 and its approval of a generic version in 2019. But it ruled to roll back FDA actions to expand access to mifepristone and return to pre-2016 regulations that included a requirement for people to access the drug in person. Such restrictions, if allowed to take effect, would prohibit the drug from being sent through the mail or prescribed through telemedicine, making it much more difficult for patients to obtain abortion care in most states. 

“This appeals court decision sets up a showdown at the Supreme Court over baseless attacks on medication abortion, which has been a lifeline since the high court reversed Roe last year,” said Nancy Northup, president and CEO of the Center for Reproductive Rights. “This order, if allowed to take effect, could jeopardize the FDA’s entire scientific system of drug approvals and would leave patients panicked and confused about their health and safety.”

White House Statement Criticizes Ruling

“If the Fifth Circuit’s ruling stands, it will significantly roll back the ability for women in every state to get the health care they need, and undermine FDA’s scientific, evidence-based process for approving safe and effective medications that patients rely on.”

Case Threatens Abortion Access  

Medication abortion is the most commonly used method of abortion in the United States, currently accounting for more than half (53%) of all abortions. In 2020, 98% of medication abortions used mifepristone.  

Since its approval, mifepristone has established a well-documented safety record, as demonstrated by its real-world use by more than five million people as well as hundreds of additional high-quality studies. 

Since Roe v. Wade was overturned in 2022, 14 states have made abortion illegal. This case threatens to restrict people’s access to abortion in states throughout the country.  

Prior to the Fifth Circuit’s August 16 ruling, court decisions in Alliance for Hippocratic Medicine v. FDA related to a preliminary injunction have included: 

  • A sweeping decision by a federal district court in Texas attempting to revoke the long-standing FDA approval of mifepristone.  
  • A Fifth Circuit ruling refusing to block the district court’s order.  
  • A stay issued by the U.S. Supreme Court preventing the district court’s order from taking effect.

The Center and its movement partners submitted amicus briefs in the case supporting the FDA and its actions.

Alliance for Hippocratic Medicine v. FDA: Complete Case InformationAlliance for Hippocratic Medicine v. FDA: Complete Case Information link

Alliance for Hippocratic Medicine v. FDA: Complete Case Information

Read more about the case here.

FDA Actions Sought to Increase Access to Medication Abortion 

In recent years, the FDA has updated its regulations and labeling to increase access to medication abortion. Among those actions are: 

  • 2016: FDA updates and approves a new evidence-based regimen and drug label for mifepristone, which expands the use of the mifepristone/misoprostol regimen from 49 days to up to 70 days (10 weeks) of pregnancy. It also broadens the provider certification requirement from physicians-only to include other advanced practice clinicians (e.g., nurse practitioners and physician assistants).  
  • 2019: FDA approves the generic version of mifepristone.  
  • 2021: FDA exercises enforcement discretion for the in-person dispensing requirement during the COVID-19 public health emergency, removing the in-person dispensing requirement for mifepristone and expanding distribution to include certified pharmacies in addition to certified clinicians. 
  • 2023: FDA permanently removes the in-person dispensing requirement for the drug and allows retail and online pharmacies to directly provide the medication to patients with prescriptions.

Read the court’s ruling and more about the case:

  • Fifth Circuit Court of Appeals Ruling, 08.16.23
  • Alliance for Hippocratic Medicine v. FDA 

Tags: mifepristone, medication abortion, FDA, u.s. food and drug administration, Alliance for Hippocratic Medicine v. FDA, medication abortion access, mifepristone access

Related Posts

TRUST WOMEN FOUNDATION, INC. vs. MARC BENNETT, ET AL.

Abortion,United States,In the Courts

Kansas Telemedicine Ban Blocked, Allowing Expansion of Medication Abortion Services

The use of telemedicine is an important tool for increasing access to abortion care, especially in remote and underserved areas.

Abortion, Legal Restrictions,United States,In the Courts
<strong>Kansas Telemedicine Ban Blocked, Allowing Expansion of Medication Abortion Services</strong>

The Center and Movement Partners Urge Court to Block Unprecedented Ruling Rejecting FDA’s Approval of Abortion Drug

Amicus brief of more than 100 reproductive rights, health, and justice partners highlights the proven safety and efficacy of the...

Abortion, Legal Restrictions,United States,In the Courts
The Center and Movement Partners Urge Court to Block Unprecedented Ruling Rejecting FDA’s Approval of Abortion Drug

Sign up for email updates.

The most up-to-date news on reproductive rights, delivered straight to you.

Footer Menu

  • Careers
  • Privacy Policy
  • Gift Acceptance Policy
  • Contact Us

Center for Reproductive Rights
© (1992-2024)

Use of this site signifies agreement with our disclaimer and privacy policy.

Better Business Bureau Charity Watch Top Rated Center for Reproductive Rights
This site uses necessary, analytics and social media cookies to improve your experience and deliver targeted advertising. Click "Options" or click here to learn more and customize your cookie settings, otherwise please click "Accept" to proceed.
OPTIONSACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_UA-6619340-11 minuteNo description
_gid1 dayThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.
_parsely_session30 minutesThis cookie is used to track the behavior of a user within the current session.
HotJar: _hjAbsoluteSessionInProgress30 minutesNo description
HotJar: _hjFirstSeen30 minutesNo description
HotJar: _hjid1 yearThis cookie is set by Hotjar. This cookie is set when the customer first lands on a page with the Hotjar script. It is used to persist the random user ID, unique to that site on the browser. This ensures that behavior in subsequent visits to the same site will be attributed to the same user ID.
HotJar: _hjIncludedInPageviewSample2 minutesNo description
HotJar: _hjIncludedInSessionSample2 minutesNo description
HotJar: _hjTLDTestsessionNo description
SSCVER1 year 24 daysThe domain of this cookie is owned by Nielsen. The cookie is used for online advertising by creating user profile based on their preferences.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
CookieDurationDescription
_fbp3 monthsThis cookie is set by Facebook to deliver advertisement when they are on Facebook or a digital platform powered by Facebook advertising after visiting this website.
fr3 monthsThe cookie is set by Facebook to show relevant advertisments to the users and measure and improve the advertisements. The cookie also tracks the behavior of the user across the web on sites that have Facebook pixel or Facebook social plugin.
IDE1 year 24 daysUsed by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
IMRID1 year 24 daysThe domain of this cookie is owned by Nielsen. The cookie is used for storing the start and end of the user session for nielsen statistics. It helps in consumer profiling for online advertising.
personalization_id2 yearsThis cookie is set by twitter.com. It is used integrate the sharing features of this social media. It also stores information about how the user uses the website for tracking and targeting.
TDID1 yearThe cookie is set by CloudFare service to store a unique ID to identify a returning users device which then is used for targeted advertising.
test_cookie15 minutesThis cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
adEdition1 dayNo description
akaas_MSNBC10 daysNo description
cookielawinfo-checkbox-functional1 yearThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-others1 yearNo description
geoEdition1 dayNo description
next-i18next1 yearNo description
SAVE & ACCEPT
Powered by CookieYes Logo
Scroll Up